Low expression of IGFBP-3 predicts poor prognosis in patients with esophageal squamous cell carcinoma

Medical Oncology

Volumn 29, Issue 4, 2012, Pages 2669-2676

  Zhao, Lei ^a   He, Li Ru ^a   Zhang, Rui ^a   Cai, Mu Yan ^a   Liao, Yi Ji ^a   Qian, Dong ^a   Xi, Mian ^a   Zeng, Yi Xin ^a   Xie, Dan ^a   Liu, Meng Zhong ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Esophageal squamous cell carcinoma; IGFBP 3; Immunohistochemistry; Insulin like growth factor

Indexed keywords

SOMATOMEDIN BINDING PROTEIN 3;

ADULT; ARTICLE; CANCER CLASSIFICATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 84867994458     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-0133-4     Document Type: Article

References (33)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90. doi: 10.3322/caac.20107.
2. Suntharalingam M. Definitive chemoradiation in the management of locally advanced esophageal cancer. Semin Radiat Oncol. 2007;17(1):22-8. doi: 10.1016/j.semradonc.2006.09.008.
3. Rohatgi PR, Swisher SG, Correa AM, Wu TT, Liao Z, Komaki R et al. Failure patterns correlate with the proportion of residual carcinoma after preoperative chemoradiotherapy for carcinoma of the esophagus. Cancer. 2005;104(7):1349-55. doi: 10.1002/cncr.21346.
4. Di Fiore F, Lecleire S, Rigal O, Galais MP, Ben Soussan E, David I, et al. Predictive factors of survival in patients treated with definitive chemoradiotherapy for squamous cell esophageal carcinoma. World J Gastroenterol. 2006;12(26):4185-90.
5. Luthra R, Wu TT, Luthra MG, Izzo J, Lopez-Alvarez E, Zhang L et al. Gene expression profiling of localized esophageal carcinomas: association with pathologic response to preoperative chemoradiation. J Clin Oncol. 2006;24(2):259-67. doi: 10.1200/JCO.2005.03.3688.
6. He LR, Liu MZ, Li BK, Rao HL, Liao YJ, Guan XY et al. Prognostic impact of H3K27me3 expression on locoregional progression after chemoradiotherapy in esophageal squamous cell carcinoma. BMC Cancer. 2009;9:461. doi: 10.1186/1471-2407-9-461.
7. He LR, Liu MZ, Li BK, Jia WH, Zhang Y, Liao YJ et al. High expression of EZH2 is associated with tumor aggressiveness and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy. Int J Cancer. 2010;127(1):138-47. doi: 10.1002/ijc.25031.
8. He LR, Liu MZ, Li BK, Rao HL, Liao YJ, Zhang LJ et al. Clusterin as a predictor for chemoradiotherapy sensitivity and patient survival in esophageal squamous cell carcinoma. Cancer Sci. 2009;100(12):2354-60. doi: 10.1111/j.1349-7006.2009.01349.x.
9. Hollowood AD, Lai T, Perks CM, Newcomb PV, Alderson D, Holly JM. IGFBP-3 prolongs the p53 response and enhances apoptosis following UV irradiation. Int J Cancer. 2000;88(3):336-41. doi: 10.1002/1097-0215(20001101)88:3<336::AID- IJC3>3.0.CO;2-A.
10. Hwa V, Oh Y, Rosenfeld RG. The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev. 1999;20(6):761-87.
11. Rajah R, Valentinis B, Cohen P. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem. 1997;272(18):12181-8.
12. Williams AC, Collard TJ, Perks CM, Newcomb P, Moorghen M, Holly JM, et al. Increased p53-dependent apoptosis by the insulin-like growth factor binding protein IGFBP-3 in human colonic adenoma-derived cells. Cancer Res. 2000;60(1):22-7.
13. Takaoka M, Harada H, Andl CD, Oyama K, Naomoto Y, Dempsey KL et al. Epidermal growth factor receptor regulates aberrant expression of insulin-like growth factor-binding protein 3. Cancer Res. 2004;64(21):7711-23. doi: 10.1158/0008-5472.CAN-04-0715.
14. Yoshino K, Motoyama S, Koyota S, Shibuya K, Usami S, Maruyama K et al. IGFBP3 and BAG1 enhance radiation-induced apoptosis in squamous esophageal cancer cells. Biochem Biophys Res Commun. 2011;404(4):1070-5. doi: 10.1016/j.bbrc.2010.12.115.
15. Zhao Z, Liu Y, He H, Chen X, Chen J, Lu YC. Candidate genes influencing sensitivity and resistance of human glioblastoma to Semustine. Brain Res Bull. 2011;86(3-4):189-94. doi: 10.1016/j.brainresbull.2011.07.010.
16. Guo BH, Zhang X, Zhang HZ, Lin HL, Feng Y, Shao JY et al. Low expression of Mel-18 predicts poor prognosis in patients with breast cancer. Ann Oncol. 2010;21(12):2361-9. doi: 10.1093/annonc/mdq241.
17. Xiong J, Yang Q, Kang J, Sun Y, Zhang T, Margaret G et al. Simultaneous isolation of DNA, RNA, and protein from Medicago truncatula L. Electrophoresis. 2010. doi: 10.1002/elps.201000425.
18. Butt AJ, Firth SM, King MA, Baxter RC. Insulin-like growth factor-binding protein-3 modulates expression of Bax and Bcl-2 and potentiates p53-independent radiation-induced apoptosis in human breast cancer cells. J Biol Chem. 2000;275(50):39174-81. doi: 10.1074/jbc.M908888199M908888199.
19. Baxter RC, Butt AJ, Schedlich LJ, Martin JL. Antiproliferative and pro-apoptotic activities of insulin-like growth factor-binding protein-3. Growth Horm IGF Res. 2000;10 Suppl A:S10-1.
20. Oh Y, Muller HL, Lamson G, Rosenfeld RG. Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells. Cell surface binding and growth inhibition. J Biol Chem. 1993;268(20):14964-71.
21. Butt AJ, Williams AC. IGFBP-3 and apoptosisa license to kill? Apoptosis. 2001;6(3):199-205.
22. Gill ZP, Perks CM, Newcomb PV, Holly JM. Insulin-like growth factor-binding protein (IGFBP-3) predisposes breast cancer cells to programmed cell death in a non-IGF-dependent manner. J Biol Chem. 1997;272(41):25602-7.
23. Collard TJ, Guy M, Butt AJ, Perks CM, Holly JM, Paraskeva C, et al. Transcriptional upregulation of the insulin-like growth factor binding protein IGFBP-3 by sodium butyrate increases IGF-independent apoptosis in human colonic adenoma-derived epithelial cells. Carcinogenesis. 2003;24(3):393-401.
24. Torng PL, Lee YC, Huang CY, Ye JH, Lin YS, Chu YW et al. Insulin-like growth factor binding protein-3 (IGFBP-3) acts as an invasion-metastasis suppressor in ovarian endometrioid carcinoma. Oncogene. 2008;27(15):2137-47. doi: 10.1038/sj.onc.1210864.
25. Torng PL, Lin CW, Chan MW, Yang HW, Huang SC, Lin CT. Promoter methylation of IGFBP-3 and p53 expression in ovarian endometrioid carcinoma. Mol Cancer. 2009;8:120. doi: 10.1186/1476-4598-8-120.
26. Chang YS, Wang L, Liu D, Mao L, Hong WK, Khuri FR, et al. Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer. Clin Cancer Res. 2002;8(12):3669-75.
27. Tomii K, Tsukuda K, Toyooka S, Dote H, Hanafusa T, Asano H et al. Aberrant promoter methylation of insulin-like growth factor binding protein-3 gene in human cancers. Int J Cancer. 2007;120(3):566-73. doi: 10.1002/ijc.22341.
28. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev. 2002;23(6):824-54.
29. Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet. 2000;16(4):168-74. doi: S0168-9525(99)01971-X.
30. Hanafusa T, Yumoto Y, Nouso K, Nakatsukasa H, Onishi T, Fujikawa T et al. Reduced expression of insulin-like growth factor binding protein-3 and its promoter hypermethylation in human hepatocellular carcinoma. Cancer Lett. 2002;176(2):149-58. doi: S0304383501007364.
31. Ibanez de Caceres I, Dulaimi E, Hoffman AM, Al-Saleem T, Uzzo RG, Cairns P. Identification of novel target genes by an epigenetic reactivation screen of renal cancer. Cancer Res. 2006;66(10):5021-8. doi: 10.1158/0008-5472.CAN-05- 3365.
32. Wiley A, Katsaros D, Chen H, Rigault de la Longrais IA, Beeghly A, Puopolo M et al. Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential. Cancer. 2006;107(2):299-308. doi: 10.1002/cncr.21992.
33. Ikeda G, Isaji S, Chandra B, Watanabe M, Kawarada Y. Prognostic significance of biologic factors in squamous cell carcinoma of the esophagus. Cancer. 1999;86(8):1396-405. doi: 10.1002/(SICI)1097-0142(19991015)86:8<1396: :AID-CNCR3>3.0.CO;2-H.